<DOC>
	<DOC>NCT02108639</DOC>
	<brief_summary>Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325.</brief_summary>
	<brief_title>To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet</brief_title>
	<detailed_description>IND Number: 79,599/101,943 Primary Purpose: Other - Phase 1 Clinical Pharmacology study to determine the effect of renal impairment on the exposure of DCV, ASV, BMS-791325 (fixed dosed combination) and BMS-791325 given in multiple doses Fixed dose combination (FDC) Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (DCV 3DAA FDC)</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects in Group A must be in good health and have normal renal function Subjects in Groups BE may have clinical, Electrocardiogram (ECG) and laboratory findings consistent with their degree of renal dysfunction Women of childbearing potential (WOCBP) and male participants must agree to follow the required contraceptive methods Subjects in Group A must not have any significant acute or chronic illnesses Subjects in Groups BE must not have uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, and/or neurological disease within 6 months of screening Subjects in Groups BE may not have evidence of rapidly deteriorating renal function, defined as a screening creatinine clearance (CLcr) which has decreased from a previous CLcr by 50% within the last 3 months Prior exposure to DCV, ASV or BMS791325 within 3 months prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>